Saltar al contenido
Merck
Todas las fotos(1)

Documentos

Y0001031

Lamotrigine for peak identification

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Lamotrigine, 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, GI 267119X

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C9H7Cl2N5
Número de CAS:
84057-84-1
Peso molecular:
256.09
MDL number:
MFCD00865333
UNSPSC Code:
41116107
PubChem Substance ID:
329831228
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lamotrigine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

InChI key

PYZRQGJRPPTADH-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamotrigine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anticonvulsant.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

Y0001085

Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001030

Lamotrigine, European Pharmacopoeia (EP) Reference Standard

Y0001032

2,3-Dichlorobenzoic acid, European Pharmacopoeia (EP) Reference Standard

1356778

2,3-Dichlorobenzoic acid, United States Pharmacopeia (USP) Reference Standard

1356790

Lamotrigine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1356789

Lamotrigine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1368

2,3-Dichlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1392

Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material

BP1097

Lamotrigine, British Pharmacopoeia (BP) Reference Standard

BP1098

Lamotrigine impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR8729

Lamotrigine Related Compound C, certified reference material, pharmaceutical secondary standard

PHR8730

Lamotrigine Related Compound D, certified reference material, pharmaceutical secondary standard

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Maxine Dibué et al.
Epilepsia, 54(9), 1542-1550 (2013-06-19)
Lamotrigine (LTG) is a popular modern antiepileptic drug (AED); however, its mechanism of action has yet to be fully understood, as it is known to modulate many members of several ion channel families. In heterologous systems, LTG inhibits Cav 2.3
Allyson K Friedman et al.
Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)
Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA
Chaitali Ghosh et al.
Epilepsia, 54(9), 1562-1570 (2013-07-20)
Brain drug bioavailability is regulated by the blood-brain barrier (BBB). It was recently suggested that cytochrome P450 (CYP) enzymes could act in concert with multidrug transporter proteins to regulate drug penetration and distribution into the diseased brain. The possibility that
Shai Sandalon et al.
Experimental eye research, 115, 47-56 (2013-07-03)
Voltage gated sodium channels (Nav), are proposed mediators of neuronal damage in ischemic and excitotoxicity disease models. We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models. Additionally, expression of the
Stacey Shim et al.
The Journal of pharmacology and experimental therapeutics, 347(2), 487-496 (2013-08-30)
Carisbamate and lamotrigine are anticonvulsants that act on neuronal voltage-gated sodium channels. Carisbamate has shown antidepressant-like effects in animal models of depression, and lamotrigine is a mood stabilizer with a therapeutic effect in depressive episodes of patients with bipolar disorder.
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico